# Allergy Therapeutics plc (AGY.L) fundamentals

Data as of 2026-09-08. LSE, United Kingdom. Sector: Healthcare / Pharmaceuticals. Price 5p, market value 317 millionp.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Allergy Therapeutics plc reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 2.8×**. Each dollar of revenue is priced at 2.8×.
- **Price / book: 50.0×**. The shares trade at 50.0× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -22.1%** (5-yr avg -1.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 47.5%**. Allergy Therapeutics plc keeps 47.5% of revenue after the direct cost of what it sells.
- **Operating margin: -57.2%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -72.9%**. The company reported a net loss over the last twelve months.
- **Return on equity: 142.3%**. A 142.3% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: -338.3%**. Return on all capital, debt included, is -338.3%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -125.3%**. Each dollar of assets produces -125.3% of profit.

## Growth
- **Revenue growth (1 yr): -0.3%** (3-yr -8.9%/yr, 5-yr -6.8%/yr). Revenue fell 0.3% over the last year, against -6.8% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 21.5%**. Earnings per share rose 21.5%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Net debt / EBITDA: net cash**. Allergy Therapeutics plc holds more cash than debt.
- **Interest coverage: -5.5×**. Operating profit covers interest only -5.5×: fragile.
- **Current ratio: 1.28** (quick 0.76). Current assets cover the next year's liabilities 1.28 times.
- **Altman Z-score: 0.91**. A Z-score of 0.91 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Allergy Therapeutics plc does not currently pay a dividend, but it returned 11.7% of its market value through buybacks over the last year.

## Analyst view
- **Analyst consensus: strong_buy** (1 analyst). 1 analysts cover Allergy Therapeutics plc; the consensus is strong_buy, with an average price target of 13p (+160% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -38.2%** (YTD -52.3%, 3-mo -38.2%). The shares are down 38.2% over twelve months including dividends.
- **From 52-week high: -58.7%** (10.9% above the low). Trading 59% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 41**. An RSI of 41 is neutral.
- **Beta (1 yr): -0.44** (volatility 62%). Beta of -0.44 against the FTSE All-Share: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AGY.L · Page: https://foliofundamentals.com/stocks/agy.l

Not investment advice.